Transcept Pharmaceuticals Inc  

(Public, NASDAQ:TSPT)   Watch this stock  
Find more results for TSPT
1.95
+0.03 (1.56%)
Real-time:   10:38AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.85 - 1.95
52 week 1.80 - 3.90
Open 1.94
Vol / Avg. 4,261.00/46,703.00
Mkt cap 37.36M
P/E     -
Div/yield 0.67
EPS -0.87
Shares 19.16M
Beta 0.80
Inst. own 67%
Nov 5, 2014
Q3 2014 Transcept Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Oct 28, 2014
Transcept Pharmaceuticals Inc Extraordinary Shareholders Meeting Add to calendar
Aug 11, 2014
Q2 2014 Transcept Pharmaceuticals Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -918.78% -1571.04%
Operating margin -912.15% -1566.74%
EBITD margin - -1374.30%
Return on average assets -23.05% -31.96%
Return on average equity -23.97% -32.84%
Employees 8 -
CDP Score - -

Address

Suite #110, 1003 W. Cutting Blvd
POINT RICHMOND, CA 94804
United States - Map
+1-510-2153500 (Phone)
+1-510-2153535 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Transcept Pharmaceuticals, Inc. (Transcept) is a specialty pharmaceutical company focused on the development and commercialization of products that address therapeutic needs in the field of neuroscience. In November 2011, the United States Food and Drug Administration (FDA) approved its new drug application (NDA) for Intermezzo (zolpidem tartrate) sublingual tablet C-IV for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. In March 2011, the Company began a Phase II study of TO-2061, a low dose of ondansetron adjunctive treatment for patients with obsessive compulsive disorder (OCD), who has not adequately responded to first-line therapy.

Officers and directors

Glenn A. Oclassen Chairman of the Board, President, Chief Executive Officer
Age: 71
Bio & Compensation  - Reuters
Leone D. Patterson Chief Financial Officer, Vice President
Age: 51
Bio & Compensation  - Reuters
Nikhilesh N. Singh Ph.D. Senior Vice President, Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
John A. Kollins Senior Vice President, Chief Business Officer
Age: 51
Bio & Compensation  - Reuters
G. Kirk Raab Lead Independent Director
Age: 78
Bio & Compensation  - Reuters
Thomas J. Dietz Ph.D. Independent Director
Age: 51
Bio & Compensation  - Reuters
Thomas D. Kiley Esq. Independent Director
Age: 71
Bio & Compensation  - Reuters
Matthew M. Loar CPA Independent Director
Age: 50
Bio & Compensation  - Reuters
Jake R. Nunn Independent Director
Age: 43
Bio & Compensation  - Reuters